News

New Medtronic Data Show Additional Clinical Advantages in Pacing Both Ventricles Versus Conventional Right-Ventricular Pacing Medtronic, Inc. announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or...

Late-breaking data presented at Heart Rhythm Society’s 2013 Annual Meeting show benefits compared with single chamber devices sustained in long-term follow-up Sorin Group, a global medical company and a leader in the treatment of...

Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope reduced major infection rates by more than 90% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to similar high-risk cohorts,...

 Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a...

Validating its leadership in shock reduction research and technology, Medtronic, Inc. (NYSE: MDT) today announced the results of three clinical trials, Shock-Less, PainFree SST and ADVANCE III, which successfully employed key strategies to...

The Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA) and Asia Pacific Heart Rhythm Society (APHRS), release the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited...

The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at least three years after index hospitalization...

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has conducted a further independent analysis of data received...

GE Healthcare introduced today, during the Heart Rhythm Society’s (HRS) 34th Annual Scientific Sessions, Innova EPVision 2.0, an application that combines information from EP recording and live fluoroscopy, and Dose Blueprint, a comprehensive...

nContact, Inc. today announced that it has received conditional approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective,...